<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02393352</url>
  </required_header>
  <id_info>
    <org_study_id>UAL_435</org_study_id>
    <nct_id>NCT02393352</nct_id>
  </id_info>
  <brief_title>Benefits of Dry Needling in Trigger Points on Autonomic Nervous System and Corporal Composition in Patients With Fibromyalgia Syndrome</brief_title>
  <official_title>Benefits of Dry Needling in Trigger Points on Autonomic Nervous System, Photoelectric Plethysmography, Body Composition in Patients With Fibromyalgia Syndrome.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidad de Almeria</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universidad de Almeria</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the benefits of dry needling in trigger points on autonomic nervous
      system, photoelectric plethysmography, body composition in patients with fibromyalgia
      syndrome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dru needling can be developed on active trigger points. Myofascial trigger points can be
      active or latent. An active myofascial trigger point pain causes giving a specific
      pathological picture. We will conduct a location of myofascial trigger points following the
      illustrations location myofascial trigger points that indicate Travell and Simons both
      left-sided and right.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Actual">February 2017</completion_date>
  <primary_completion_date type="Actual">November 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes Scores on Visual Analoge Scale</measure>
    <time_frame>At baseline and 4 weeks</time_frame>
    <description>Intensity of pain (within McGill questionnaire)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes Scores on Percentage Evaluation Peripheral Capillary Oxygen saturation and photoelectric plethysmograph (Analysis of pulse wave and PANI)</measure>
    <time_frame>At baseline and 4 weeks</time_frame>
    <description>Cardiac output. Reflectivity index. Stiffness index. Oxygen saturation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change Scores on Body Composition</measure>
    <time_frame>At baseline and 4 weeks</time_frame>
    <description>Fat mass. Body fat mass. Intracellular water. Extracellular water. Fat-free mass. Total body water.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes Scores on Cholinergic response indicators (%).</measure>
    <time_frame>At baseline and 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes Scores on Heart rate variability.</measure>
    <time_frame>At baseline and 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes Scores on Valsalva ratio. K30/15.</measure>
    <time_frame>At baseline and 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes Scores on Systemic vascular resistance.</measure>
    <time_frame>At baseline and 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes Scores on Systolic pressure.</measure>
    <time_frame>At baseline and 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes Scores on Diastolic pressure.</measure>
    <time_frame>At baseline and 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes Scores on Assessment of autonomic nervous system</measure>
    <time_frame>At baseline and 4 weeks</time_frame>
    <description>Galvanic response estimate.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Fibromyalgia</condition>
  <condition>Trigger Points</condition>
  <arm_group>
    <arm_group_label>Dry Needling Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The dry needling therapy will be applied on active trigger points in occipital muscle, splenius capitis, sternocleidomastoid muscle, scalene muscles, trapezius, supraspinatus, infraspinatus muscle, latissimus dorsi, iliocostalis muscle, multifidus muscles, and quadratus lumbourm muscles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Electrical Stimulation Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Diadynamic fixed current phase in active trigger points, with pulses of 10msec, and intervals of equal duration.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Dry Needling Therapy</intervention_name>
    <description>The dry needling therapy will be applied on active trigger points in occipital muscle, splenius capitis, sternocleidomastoid muscle, scalene muscles, trapezius, supraspinatus, infraspinatus muscle, latissimus dorsi, iliocostalis muscle, multifidus muscles, and quadratus lumbourm muscles.</description>
    <arm_group_label>Dry Needling Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Electrical Stimulation Therapy</intervention_name>
    <arm_group_label>Electrical Stimulation Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Fibromyalgia syndrome diagnosis.

          -  Aged from 18 to 65 years.

          -  No regular physical activity.

          -  Limitation of usual activities due to pain on at least 1 day in the previous 30 days.

          -  Agreement to attend evening therapy sessions.

        Exclusion Criteria:

          -  Severe physical disability.

          -  Comorbid conditions (eg, morbid obesity, inflammatory diseases, irritable bowel
             syndrome, interstitial cystitis).

          -  Uncontrolled endocrine disorders (eg, hyperthyroidism or hypothyroidism, diabetes).

          -  Malignancy.

          -  Psychiatric.

          -  Illnesses (eg, schizophrenia or substance abuse).

          -  Medication usage other than as-needed analgesics (excluding long-term narcotics).

          -  History of surgery.

          -  History of whiplash injury.

          -  Presence of a score &gt;9 points in the Beck Depression Inventory.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Adelaida María Castro-Sánchez</name>
      <address>
        <city>Almería</city>
        <zip>04120</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Katz RS, Mease P, Russell AS, Russell IJ, Winfield JB, Yunus MB. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res (Hoboken). 2010 May;62(5):600-10. doi: 10.1002/acr.20140.</citation>
    <PMID>20461783</PMID>
  </reference>
  <reference>
    <citation>Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, Tugwell P, Campbell SM, Abeles M, Clark P, et al. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum. 1990 Feb;33(2):160-72.</citation>
    <PMID>2306288</PMID>
  </reference>
  <reference>
    <citation>Arnold LM, Clauw DJ, McCarberg BH; FibroCollaborative. Improving the recognition and diagnosis of fibromyalgia. Mayo Clin Proc. 2011 May;86(5):457-64. doi: 10.4065/mcp.2010.0738. Review.</citation>
    <PMID>21531887</PMID>
  </reference>
  <reference>
    <citation>Goldenberg DL. Fibromyalgia syndrome: an emerging but controversial condition. JAMA. 2014 Apr 16;311(15):1570. doi: 10.1001/jama.2013.279453.</citation>
    <PMID>24737378</PMID>
  </reference>
  <reference>
    <citation>Castro-Sánchez AM, Matarán-Peñarrocha GA, Sánchez-Labraca N, Quesada-Rubio JM, Granero-Molina J, Moreno-Lorenzo C. A randomized controlled trial investigating the effects of craniosacral therapy on pain and heart rate variability in fibromyalgia patients. Clin Rehabil. 2011 Jan;25(1):25-35. doi: 10.1177/0269215510375909. Epub 2010 Aug 11.</citation>
    <PMID>20702514</PMID>
  </reference>
  <reference>
    <citation>Hidalgo-Lozano A, Fernández-de-las-Peñas C, Díaz-Rodríguez L, González-Iglesias J, Palacios-Ceña D, Arroyo-Morales M. Changes in pain and pressure pain sensitivity after manual treatment of active trigger points in patients with unilateral shoulder impingement: a case series. J Bodyw Mov Ther. 2011 Oct;15(4):399-404. doi: 10.1016/j.jbmt.2010.12.003. Epub 2011 Jan 17.</citation>
    <PMID>21943613</PMID>
  </reference>
  <reference>
    <citation>Pastor Mira MÁ, Lledó Boyer A, López-Roig S, Pons Calatayud N, Martín-Aragón Gelabert M. [Predictors of healthcare resource use in fibromyalgia]. Psicothema. 2010 Nov;22(4):549-55. Spanish.</citation>
    <PMID>21044477</PMID>
  </reference>
  <reference>
    <citation>Castro-Sánchez AM, Matarán-Peñarrocha GA, Granero-Molina J, Aguilera-Manrique G, Quesada-Rubio JM, Moreno-Lorenzo C. Benefits of massage-myofascial release therapy on pain, anxiety, quality of sleep, depression, and quality of life in patients with fibromyalgia. Evid Based Complement Alternat Med. 2011;2011:561753. doi: 10.1155/2011/561753. Epub 2010 Dec 28.</citation>
    <PMID>21234327</PMID>
  </reference>
  <reference>
    <citation>Giamberardino MA, Affaitati G, Fabrizio A, Costantini R. Effects of treatment of myofascial trigger points on the pain of fibromyalgia. Curr Pain Headache Rep. 2011 Oct;15(5):393-9. doi: 10.1007/s11916-011-0205-3. Review.</citation>
    <PMID>21541831</PMID>
  </reference>
  <reference>
    <citation>Affaitati G, Costantini R, Fabrizio A, Lapenna D, Tafuri E, Giamberardino MA. Effects of treatment of peripheral pain generators in fibromyalgia patients. Eur J Pain. 2011 Jan;15(1):61-9. doi: 10.1016/j.ejpain.2010.09.002.</citation>
    <PMID>20889359</PMID>
  </reference>
  <reference>
    <citation>Alonso-Blanco C, Fernández-de-Las-Peñas C, de-la-Llave-Rincón AI, Zarco-Moreno P, Galán-Del-Río F, Svensson P. Characteristics of referred muscle pain to the head from active trigger points in women with myofascial temporomandibular pain and fibromyalgia syndrome. J Headache Pain. 2012 Nov;13(8):625-37. doi: 10.1007/s10194-012-0477-y. Epub 2012 Aug 31.</citation>
    <PMID>22935970</PMID>
  </reference>
  <reference>
    <citation>Alonso-Blanco C, Fernández-de-las-Peñas C, Morales-Cabezas M, Zarco-Moreno P, Ge HY, Florez-García M. Multiple active myofascial trigger points reproduce the overall spontaneous pain pattern in women with fibromyalgia and are related to widespread mechanical hypersensitivity. Clin J Pain. 2011 Jun;27(5):405-13. doi: 10.1097/AJP.0b013e318210110a.</citation>
    <PMID>21368661</PMID>
  </reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 4, 2015</study_first_submitted>
  <study_first_submitted_qc>March 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 19, 2015</study_first_posted>
  <last_update_submitted>October 30, 2017</last_update_submitted>
  <last_update_submitted_qc>October 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universidad de Almeria</investigator_affiliation>
    <investigator_full_name>Adelaida María Castro-Sánchez</investigator_full_name>
    <investigator_title>PhD (Lecturer)</investigator_title>
  </responsible_party>
  <keyword>Body Composition</keyword>
  <keyword>Autonomic Nervous System</keyword>
  <keyword>Oxygen</keyword>
  <keyword>Randomized Controlled Trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibromyalgia</mesh_term>
    <mesh_term>Myofascial Pain Syndromes</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

